GAINESVILLE, Fla., March 15, 2017 /PRNewswire/ -- Captozyme Inc., a biotechnology company focused on therapeutic
"We are humbled by the confidence put in us to continue our research and develop products for marketplace introduction," said Aaron Cowley, PhD, Captozyme Co-founder. "Our team remains dedicated to making Captozyme products serve the needs of our most important stakeholders, the people who are currently struggling on a low-oxalate diet."
Mark S. Long, Director of the Sid Martin Biotechnology Institute, commented, "This new funding is additional validation of the significance of Captozyme proprietary research and the company's strong product pipeline in the medical foods and orphan drug markets."
Nephure Pre-Clinical Data
The goal of Nephure is to make being healthier and following a low-oxalate diet easier. Normal consumption of calcium is useful in normalizing relatively high urinary oxalate. Sticking to a low-oxalate diet can be challenging, especially when there can be a wide range of discrepancies online about what food is generally considered oxalate-rich. Nephure takes away this uncertainty by breaking down the oxalate compound in food.
A low-oxalate diet should limit oxalate intake to 40-50 mg daily, although in the U.S. oxalate intake is estimated to average 150-200 mg every day.
Captozyme's pre-clinical data of Nephure features:
Developed from years of rigorous scientific research, Nephure is a safe, effective solution that aids a low-oxalate diet by breaking down the oxalate and increasing the food's nutritional value.
About Captozyme, Inc.
Captozyme, Inc. is a biotechnology company dedicated to helping people better manage their diets and overall health. The company plans to launch Nephure in the spring of 2017. With Nephure the company has created a product that allows people to enjoy the foods they love without the consequences of adding oxalate to their bodies. Learn more about Captozyme at Captozyme.com or visit Nephure.com.
Interested in receiving more information on Nephure? Follow Nephure on Facebook, Twitter or sign up for the newsletter.
About Sid Martin Biotechnology Institute at the University of Florida
The Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit. SidMartinBio.com.
Aaron CowleyCo-founderCaptozyme Inc. 785.760.3128 Aaron.email@example.com
Merrie ShawAssistant DirectorSid Martin Biotechnology Institute386-462-0880 firstname.lastname@example.org
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/captozyme-secures-34-million-to-continue-enzyme-research-300423887.html
Subscribe to our Free Newsletters!
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...
Discectomy is a surgical procedure in which a herniated (bulged) disc that compresses the nerves of ...View All